Market Access A step forward, but not the finish line: What NICE’s QALY up... Healthcare in the UK is at an inflection point.
Market Access Beyond the Bill: how do we make medicines affordable without... Two pharmaceutical giants have paused investment in the UK. More than a setback for British life sciences, it’s a warning sign for the future.
Market Access NICE contribution to the cost per QALY threshold debate? Leela Barham sets out some wider context to the latest blog from NICE on the cost-effectiveness threshold used by the agency and highlights the opportunity for stakeholders to build their c
Views & Analysis Collaboration can ensure access to life-changing innovation As a pioneering risk sharing scheme has shown, new medications can be the catalyst for a whole new care infrastructure.
Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
Oncology LSX2026: Addressing adult eye cancer, with Roi Raz Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
